Since the start of 2016, there has been a lot of licensing activity surrounding stem cell technologies, with key agreements linked between the Coriell Institute for Medical Research and Drs. Jeanne Loring and Franz Josef Muller (access to a bioinformatics assay that can assess the pluripotency of human induced pluripotent stem cells), Avapecia Life Sciences Corporation and Oceans Five-O Development Corporation (use of a cell insolation and enrichment technology to identify stem cell candidates for cell therapy applications), and most recently, TheraKine and Cell Care Therapeutics (use of injectable sustained release technology within stem cell therapies for eye disease).
To learn more about the licensing agreement between TheraKine, in Hermosa Beach, CA, and Cell Care Therapeutics, in Long Beach, CA, see the press release issued January 14, 2016. It is printed with permission from press contact, Seth Yakatan.
TheraKine and Cell Care Therapeutics Engage in a License and Development Agreement
San Francisco, CA; January 14, 2016 07:50 ET – TheraKine, Ltd., a privately held drug delivery company, and Cell Care Therapeutics, Inc, a privately held stem cell therapeutics company, have entered into a licensing agreement to use TheraKine’s injectable sustained release technology to enable Cell Care’s stem cell therapies for diseases of the eye that commonly cause blindness.
TheraKine has developed sustained release delivery technology platforms for injectable local delivery of biologic agents and live cells.
Cell Care uses stem cells to treat degenerative and inflammatory diseases of the eye.
“It gives us all confidence to know that the effects of our proprietary regenerative therapies can be extended to many months in order to direct neuro-vascular repair and treat chronic inflammatory and degenerative ocular diseases over a clinically relevant period of time,” said Nicolas Sohl, CEO of Cell Care. “We hope that we will soon be in human studies to help prevent otherwise incurable conditions that leave people blind or disabled.”
Seth Yakatan, CEO of TheraKine, stated, “It is very exciting being part of the solution to enable many months of therapy with stem cells, using technologies we originally developed for antibodies, especially since stem cells show promise as the future of therapy for many difficult diseases.”
The companies did not disclose the terms of the license.